NO975714L - FremgangsmÕte for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmas÷ytisk blanding og diagnostisk reagens inneholdende samme - Google Patents

FremgangsmÕte for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmas÷ytisk blanding og diagnostisk reagens inneholdende samme

Info

Publication number
NO975714L
NO975714L NO975714A NO975714A NO975714L NO 975714 L NO975714 L NO 975714L NO 975714 A NO975714 A NO 975714A NO 975714 A NO975714 A NO 975714A NO 975714 L NO975714 L NO 975714L
Authority
NO
Norway
Prior art keywords
monoclonal antibody
antigens
preparation
reagent containing
diagnostic reagent
Prior art date
Application number
NO975714A
Other languages
English (en)
Other versions
NO327047B1 (no
NO975714D0 (no
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO975714D0 publication Critical patent/NO975714D0/no
Publication of NO975714L publication Critical patent/NO975714L/no
Publication of NO327047B1 publication Critical patent/NO327047B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
NO19975714A 1996-12-06 1997-12-05 Fremgangsmate for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmasoytisk blanding NO327047B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP97201972 1997-06-27

Publications (3)

Publication Number Publication Date
NO975714D0 NO975714D0 (no) 1997-12-05
NO975714L true NO975714L (no) 1998-06-08
NO327047B1 NO327047B1 (no) 2009-04-14

Family

ID=26143410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975714A NO327047B1 (no) 1996-12-06 1997-12-05 Fremgangsmate for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmasoytisk blanding

Country Status (17)

Country Link
US (3) US6020170A (no)
EP (1) EP0856520B1 (no)
JP (1) JPH10179160A (no)
KR (1) KR100543053B1 (no)
AT (1) ATE322507T1 (no)
AU (1) AU733165B2 (no)
BR (1) BR9706236A (no)
CA (1) CA2221682C (no)
DE (1) DE69735621T2 (no)
DK (1) DK0856520T3 (no)
ES (1) ES2262170T3 (no)
HU (1) HUP9702359A3 (no)
IL (1) IL122233A (no)
NO (1) NO327047B1 (no)
NZ (1) NZ329314A (no)
PL (1) PL193821B1 (no)
PT (1) PT856520E (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69934250T2 (de) * 1998-12-22 2007-05-24 Raven Biotechnologies, Inc., South San Francisco Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
SE9902817D0 (sv) 1999-07-30 1999-07-30 A & Science Invest Ab A method for selective electrofusion of at least two fusion partners having cell-like membranes
TR200201036T2 (tr) * 1999-10-18 2002-08-21 Akzo Nobel N.V. İmmünoterapide kullanmak için değiştirilmiş peptitler ve peptido-taklitleri
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
IL154000A0 (en) 2000-08-14 2003-07-31 Akzo Nobel Nv Use of antibodies against specific mhc-peptide complexes
BR0211468A (pt) * 2001-07-24 2004-11-23 Univ Yale Métodos de tratar e de prevenir uma doença inflamátoria em um mamìfero e de identificar um composto útil para tratar uma doença inflamatória em um mamìfero, composto, e kits para tratar e para prevenir uma doença inflamatória em um mamìfero
US7018819B2 (en) * 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
WO2004087911A1 (ja) * 2003-03-28 2004-10-14 Toyama New Industry Organization １個の抗原特異的ｂリンパ球を用いた抗原特異的抗体産生ハイブリドーマの作製方法及びモノクローナル抗体の製造方法
JP4934426B2 (ja) 2003-08-18 2012-05-16 メディミューン，エルエルシー 抗体のヒト化
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
WO2005081980A2 (en) * 2004-02-25 2005-09-09 Medimmune, Inc. Methods and compositions relating to chitinases and chitinase-like molecules and modulation of osteoclasts
CA2595682A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
WO2007027748A2 (en) * 2005-08-31 2007-03-08 Medimmune, Inc. C/clp antagonists and methods of use thereof
ES2537205T3 (es) * 2008-01-09 2015-06-03 Alcon Lensx, Inc. Fragmentación de tejido por láser fotodisruptor
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
WO2019105864A1 (en) 2017-11-30 2019-06-06 F. Hoffmann-La Roche Ag B-cell cultivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
IE912528A1 (en) * 1990-07-19 1992-01-29 Scripps Clinic Res Inhabition of mac-1 receptor binding fibrinogen using d30¹homologs
ZA919299B (en) * 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
EP0889964A1 (en) * 1996-03-28 1999-01-13 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins

Also Published As

Publication number Publication date
MX9709446A (es) 1998-07-31
HU9702359D0 (en) 1998-03-02
IL122233A (en) 2001-04-30
AU4690897A (en) 1998-06-11
CA2221682C (en) 2011-10-18
HUP9702359A3 (en) 2001-11-28
EP0856520A1 (en) 1998-08-05
JPH10179160A (ja) 1998-07-07
AU733165B2 (en) 2001-05-10
PL193821B1 (pl) 2007-03-30
US20020143150A1 (en) 2002-10-03
ES2262170T3 (es) 2006-11-16
PL323572A1 (en) 1998-06-08
KR19980063909A (ko) 1998-10-07
BR9706236A (pt) 1999-05-04
KR100543053B1 (ko) 2006-06-13
ATE322507T1 (de) 2006-04-15
NO327047B1 (no) 2009-04-14
PT856520E (pt) 2006-08-31
US6392020B1 (en) 2002-05-21
NZ329314A (en) 1999-02-25
EP0856520B1 (en) 2006-04-05
US6020170A (en) 2000-02-01
DE69735621T2 (de) 2006-08-24
NO975714D0 (no) 1997-12-05
DK0856520T3 (da) 2006-07-31
CA2221682A1 (en) 1998-06-06
HUP9702359A2 (hu) 1998-09-28
IL122233A0 (en) 1998-04-05
DE69735621D1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
NO975714L (no) FremgangsmÕte for fremstilling av monoklonalt antistoff, monoklonalt antistoff og farmas÷ytisk blanding og diagnostisk reagens inneholdende samme
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
DE69632667D1 (de) CTLA4-Mutantmoleküle und deren Verwendung
PT613944E (pt) Processos para a regulacao da resposta imunitaria utilizando moleculas de ligacao de ctla4 e moleculas de ligacao de il4
DE69226871D1 (de) CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen
FI100973B (fi) Menetelmä antigeenirakenteiden valmistamiseksi "Major Histocompatibili ty Complex" (MHC) luokka I -antigeeneistä ja monoklonaalisista vasta-a ineista
DE68929230D1 (de) Peptidanaloge und deren verwendung als haptene zum auslösen katalytischer antikörper
ATE142790T1 (de) Säulenagglutinationsassay und vorrichtung
EP0521996A4 (en) Catalytic antibody components
ES2116789T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y empleo.
SE8302329D0 (sv) T-cell-leukemiantigener, sett for framstellning derav och for analys av antikroppar
WO1996029409A3 (en) Rage tumor rejection antigens
NO974793D0 (no) Fremgangsmåte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav
DE3881101D1 (de) Monoklonal-antikoerper und methode fuer die bereitung von hybridoma, produzierend diese antikoerper.
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
EP0338497A3 (en) Bispecific hybrid monoclonal antibody
IT1161460B (it) Determinanti bispecifici di anticorpi procedimento per la loro preparazione ed elettrodo enzimatico comprendente tali determinanti
PL245361A1 (en) Method of obtaining antibodies specific for antigens isolated from human serum,in particular for the antigen hbs.
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees